Clinical Trials on Age-Related Immunodeficiency in Japan

Total 941 results

Kyowa Kirin Co., Ltd.

Terminated

A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration

Healthy Volunteers | Wet Age-related Macular Degeneration

Japan
Mie University

Unknown

Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration

Exudative Age-related Macular Degeneration

Japan
Nagoya City University
Novartis

Completed

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

Neovascular Age-related Macular Degeneration

Japan
Kumamoto University

Completed

Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

Age-related Macular Degeneration

Japan
Ophthalmic PDT Study Group

Completed

PDT Study for Exudative AMD With PCV

Age Related Macular Degeneration

Japan
Nihon University

Completed

Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration

Age-related Macular Degeneration

Japan
Osaka University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy

Age Related Macular Degeneration | Neovascular Maculopathy

Japan
Novartis

Completed

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

Japan
Novo Nordisk A/S

Completed

Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)

Foetal Growth Problem | Small for Gestational Age

Japan
Astellas Pharma Inc
Ono Pharmaceutical Co. Ltd

Completed

ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients

Osteoporosis | Bone Loss, Age-Related

Japan
Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan, United Kingdom
University of Jazan

Completed

Effectiveness Of Computer-Based Cognitive Training in Age-Related Cognitive Decline

Age-related Cognitive Decline

Saudi Arabia
Regeneron Pharmaceuticals

Terminated

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

Neovascular Age-Related Macular Degeneration

United States, Japan
Kyowa Kirin, Inc.

Recruiting

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)

United States, Japan, Australia, Korea, Republic of
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
Kyushu University
Novartis; Kurume University; Fukuoka University; University of Occupational and... and other collaborators

Unknown

Ranibizumab Treatment for Age-Related Macular Degeneretion (QUATRO)

Visual Disorder Due to Age-related Macula Degeneration

Japan
Novo Nordisk A/S

Completed

Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing

Foetal Growth Problem | Small for Gestational Age

Japan
Bioeq GmbH

Completed

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD)

Neovascular Age-related Macular Degeneration

Bulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
Novartis Pharmaceuticals

Completed

A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

Neovascular Age-related Macular Degeneration

Japan
AstraZeneca

Completed

A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years

Healthy Japanese Children Age 2 Years Through 6 Years

Japan
Takeda

Completed

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Primary Immunodeficiency Disease

Japan
Abbott

Completed

Special Investigation of Kaletra in Pregnant Women

Human Immunodeficiency Virus

Japan
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

Spain, Korea, Republic of, Czechia, Japan, Singapore, United States, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Portugal, Bulgaria, Latvia, Canada, Hungary, Arge... and more
Amgen
Parexel

Completed

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Spain, United States, Czechia, Serbia, Israel, Canada, Germany, Japan, Hungary, Poland, Korea, Republic of, Estonia, Hong Kong, Italy, Latvia, Lithuania, Mexico, Slovakia
Sandoz

Completed

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, Czechia, Australia, Austria, France, Germany, Hungary, Israel, Japan, Latvia, Lithuania, Poland, Portugal, Slovakia, Spain
Sam Chun Dang Pharm. Co. Ltd.

Completed

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

Neovascular Age-related Macular Degeneration

United States, Korea, Republic of, United Kingdom, Japan, Canada, Turkey, Argentina, Australia, Denmark, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Brazil, Hong Kong, Israel, Portugal, Russian Federation, Ta... and more
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Hoffmann-La Roche

Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER)

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Spain, Germany, Croatia, Japan, United Kingdom, United States, Italy, Switzerland, France, Canada, Australia, Singapore, Israel, Puerto Rico, United Arab Emirates, Bulgaria, Chile, Czechia
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Abbott

Completed

Drug Use Investigation of Kaletra

Human Immunodeficiency Virus

Japan
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
Tokyo University
Google LLC.

Enrolling by invitation

Impact of Nutrition, Sleep, and Physical Activity on Intellectual Function and Muscle Mass in Older Adults (INSPIOR)

Cognitive Function | MCI | Cognition Disorders in Old Age | Frailty/Sarcopenia

Japan
AbbVie (prior sponsor, Abbott)

Completed

Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection

Human Immunodeficiency Virus Infection

Japan
Bayer

Terminated

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration (DREAM)

Macular Degeneration

Hong Kong, Korea, Republic of, United States, Canada, Switzerland, Spain, Japan, Italy, Czech Republic, Australia, Austria, Slovakia, Germany, Hungary, Israel, Chile, France, Colombia
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S

Completed

A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects

Alcohol Dependence

Japan
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients With Alcohol Dependence

Alcohol Dependence

Japan
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S

Completed

A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence

Alcohol Dependence

Japan
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)

Alcohol Dependence

Japan
Takeda

Recruiting

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Otsuka Pharmaceutical Co., Ltd.
EPS Corporation

Completed

Comparison Study Between C13-CAC Breath Test and 24-hour Gastric pH Monitoring

Healthy | Gastric Acid-related Diseases

Japan
Pfizer

Completed

Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)

Short Stature Born Small for Gestational Age (SGA)

Japan
Novartis Pharmaceuticals

Completed

Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (EVEREST II)

Age-related Macular Degeneration | Polypoidal Choroidal Vasculopathy

Japan, Taiwan, Hong Kong, Singapore, Thailand, Korea, Republic of, Malaysia
Takeda

Recruiting

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Kyowa Kirin Co., Ltd.

Completed

A Comparative Study of KW-2246 (2246-004)

Cancer Related Pain (Breakthrough Pain)

Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
AstraZeneca

Completed

A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years

Healthy Japanese Children Age 7 Years Through 18 Years

Japan

Clinical Trials on Age-Related Immunodeficiency in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations